Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study.
Slavik M, Burkon P, Selingerova I, Krupa P, Kazda T, Stankova J, Nikl T, Hejnova R, Rehak Z, Osmera P, Prochazka T, Dvorakova E, Pospisil P, Grell P, Slampa P, Obermannova R. Slavik M, et al. Among authors: obermannova r. Medicina (Kaunas). 2021 Dec 6;57(12):1334. doi: 10.3390/medicina57121334. Medicina (Kaunas). 2021. PMID: 34946279 Free PMC article.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.
Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F. Obermannova R, et al. Eur J Cancer. 2019 Jul;116:107-113. doi: 10.1016/j.ejca.2019.05.011. Epub 2019 Jun 10. Eur J Cancer. 2019. PMID: 31195354 Clinical Trial.
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B, Budinska E, Selingerova I, Pilatova K, Fedorova L, Greplova K, Nenutil R, Valik D, Obermannova R, Sheard MA, Zdrazilova-Dubska L. Bencsikova B, et al. Among authors: obermannova r. BMC Cancer. 2019 Jul 15;19(1):687. doi: 10.1186/s12885-019-5909-5. BMC Cancer. 2019. PMID: 31307428 Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A. Holanek M, et al. Among authors: obermannova r. Cancers (Basel). 2021 Mar 30;13(7):1586. doi: 10.3390/cancers13071586. Cancers (Basel). 2021. PMID: 33808149 Free PMC article.
PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.
Obermannova R, Selingerova I, Rehak Z, Jedlicka V, Slavik M, Fabian P, Novotny I, Zemanova M, Studentova H, Grell P, Zdrazilova Dubska L, Demlova R, Harustiak T, Hejnova R, Kiss I, Vyzula R. Obermannova R, et al. Ther Adv Med Oncol. 2022 Jan 5;13:17588359211065153. doi: 10.1177/17588359211065153. eCollection 2021. Ther Adv Med Oncol. 2022. PMID: 35035533 Free PMC article.
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F. Lutz MP, et al. Among authors: obermannova r. Eur J Cancer. 2019 May;112:1-8. doi: 10.1016/j.ejca.2019.01.106. Epub 2019 Mar 15. Eur J Cancer. 2019. PMID: 30878666 Review.
Targeting HER2 for localised oesophageal cancer.
Lordick F, Obermannová R, Smyth EC. Lordick F, et al. Among authors: obermannova r. Lancet Oncol. 2022 Feb;23(2):188-190. doi: 10.1016/S1470-2045(22)00004-3. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038428 No abstract available.
55 results